Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies
- PMID:10859153
Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies
Abstract
Using human liver microsomes (HLMs) and recombinant cytochrome P450s (CYP450s), we characterized the CYP450 isoforms involved in the primary metabolic pathways of cisapride and documented the ability of cisapride to inhibit the CYP450 system. In HLMs, cisapride was N-dealkylated to norcisapride (NORCIS) and hydroxylated to 3-fluoro-4-hydroxycisapride (3-F-4-OHCIS) and to 4-fluoro-2-hydroxycisapride (4-F-2-OHCIS). Formation of NORCIS, 3-F-4-OHCIS, and 4-F-2-OHCIS in HLMs exhibited Michaelis-Menten kinetics (K(m): 23.4 +/- 8.6, 32 +/- 11, and 31 +/- 23 microM; V(max): 155 +/- 91, 52 +/- 23, and 31 +/- 23 pmol/min/mg of protein, respectively). The average in vitro intrinsic clearance (V(max)/K(m)) revealed that the formation of NORCIS was 3.9- to 5. 9-fold higher than that of the two hydroxylated metabolites. Formation rate of NORCIS from 10 microM cisapride in 14 HLMs was highly variable (range, 4.9-133.6 pmol/min/mg of protein) and significantly correlated with the activities of CYP3A (r = 0.86, P =. 0001), CYP2C19, and 1A2. Of isoform-specific inhibitors, 1 microM ketoconazole and 50 microM troleandomycin were potent inhibitors of NORCIS formation from 10 microM cisapride (by 51 +/- 9 and 44 +/- 17%, respectively), whereas the effect of other inhibitors was minimal. Of 10 recombinant human CYP450s tested, CYP3A4 formed NORCIS from 10 microM cisapride at the highest rate (V = 0.56 +/- 0. 13 pmol/min/pmol of P450) followed by CYP2C8 (V = 0.29 +/- 0.08 pmol/min/pmol of P450) and CYP2B6 (0.15 +/- 0.04 pmol/min/pmol of P450). The formation of 3-F-4-OHCIS was mainly catalyzed by CYP2C8 (V = 0.71 +/- 0.24 pmol/min/pmol of P450) and that of 4-F-2-OHCIS by CYP3A4 (0.16 +/- 0.03 pmol/min/pmol of P450). Clearly, recombinant CYP2C8 participates in cisapride metabolism, but when the in vitro intrinsic clearances obtained were corrected for abundance of each CYP450 in the liver, CYP3A4 is the dominant isoform. Cisapride was a relatively potent inhibitor of CYP2D6, with no significant effect on other isoforms tested, but the K(i) value derived (14 +/- 16 microM) was much higher than the clinically expected concentration of cisapride (<1 microM). Our data suggest that CYP3A is the main isoform involved in the overall metabolic clearance of cisapride. Cisapride metabolism is likely to be subject to interindividual variability in CYP3A expression and to drug interactions involving this isoform.
Similar articles
- Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.Desta Z, Soukhova N, Morocho AM, Flockhart DA.Desta Z, et al.J Pharmacol Exp Ther. 2001 Aug;298(2):508-20.J Pharmacol Exp Ther. 2001.PMID:11454912
- Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.Pearce RE, Gotschall RR, Kearns GL, Leeder JS.Pearce RE, et al.Drug Metab Dispos. 2001 Dec;29(12):1548-54.Drug Metab Dispos. 2001.PMID:11717173
- Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone.Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H.Kitamura A, et al.Biopharm Drug Dispos. 2005 Mar;26(2):59-65. doi: 10.1002/bdd.432.Biopharm Drug Dispos. 2005.PMID:15619261
- Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S.Patterson LH, et al.Anticancer Drug Des. 1999 Dec;14(6):473-86.Anticancer Drug Des. 1999.PMID:10834269Review.
- Cytochrome P450: new nomenclature and clinical implications.Cupp MJ, Tracy TS.Cupp MJ, et al.Am Fam Physician. 1998 Jan 1;57(1):107-16.Am Fam Physician. 1998.PMID:9447218Review.
Cited by
- Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery.Awad H, Ahmed A, Urman RD, Stoicea N, Bergese SD.Awad H, et al.Pharmgenomics Pers Med. 2019 Jul 26;12:145-154. doi: 10.2147/PGPM.S198224. eCollection 2019.Pharmgenomics Pers Med. 2019.PMID:31440074Free PMC article.
- Sucralose, a synthetic organochlorine sweetener: overview of biological issues.Schiffman SS, Rother KI.Schiffman SS, et al.J Toxicol Environ Health B Crit Rev. 2013;16(7):399-451. doi: 10.1080/10937404.2013.842523.J Toxicol Environ Health B Crit Rev. 2013.PMID:24219506Free PMC article.Review.
- Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.Johnson TN, Rostami-Hodjegan A, Tucker GT.Johnson TN, et al.Clin Pharmacokinet. 2006;45(9):931-56. doi: 10.2165/00003088-200645090-00005.Clin Pharmacokinet. 2006.PMID:16928154
- Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.Flockhart DA, Desta Z, Mahal SK.Flockhart DA, et al.Clin Pharmacokinet. 2000 Oct;39(4):295-309. doi: 10.2165/00003088-200039040-00005.Clin Pharmacokinet. 2000.PMID:11069215Review.
- Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.Desta Z, Kivistö KT, Lilja JJ, Backman JT, Soukhova N, Neuvonen PJ, Flockhart DA.Desta Z, et al.Br J Clin Pharmacol. 2001 Oct;52(4):399-407. doi: 10.1046/j.0306-5251.2001.01473.x.Br J Clin Pharmacol. 2001.PMID:11678783Free PMC article.Clinical Trial.